Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00395772 · ClinicalTrials.gov registry record · Phase 2
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 543
- Enrollment target
NCT00395772 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 543 participants.
The verdict
NCT00395772, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 543 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the optimal dose of BAY 59-7939 and to compare the safety and effectiveness of this new drug with the standard way of treatment of deep vein thrombosis (heparin infusion plus one of the vitamin K antagonists), taking into account new events of thrombosis and pulmonary embolism and bleeding risk.
Interventions
- DRUG Xarelto (Rivaroxaban, BAY59-7939)
- DRUG (LMW) Heparin + Vitamin K Antagonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 543 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00395772
The ClinicalTrials.gov registry entry for NCT00395772 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 543 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Xarelto (Rivaroxaban, BAY59-7939) is the first listed.
NCT00395772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00395772 about?
NCT00395772 is a clinical study titled "Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis". The purpose of this study is to determine the optimal dose of BAY 59-7939 and to compare the safety and effectiveness of this new drug with the standard way of treatment of deep vein thrombosis (heparin infusion plus one of the vitamin K antagonists), taking into account new events of thrombosis and...
What is the current status of trial NCT00395772?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 543 participants. The study started on 2004-12. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00395772?
The interventions under investigation include: Xarelto (Rivaroxaban, BAY59-7939) (DRUG), (LMW) Heparin + Vitamin K Antagonist (DRUG).
Who is sponsoring clinical trial NCT00395772?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.